Maiva Pharma has raised Rs 1,000 crore from Morgan Stanley Private Equity Asia and India Life Sciences Fund, including both primary and secondary funding. The funds will be used to set up a new manufacturing facility near Karnataka's Hosur, with capabilities in sterile dosage forms, including pre-filled syringes, bags, oncology, and hormonal injectables. Maiva's complex injectables development and manufacturing capability, strong compliance and regulatory standards, and transparency differentiate the company from competitors.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.